In 2010, we entered into a collaboration agreement with Takeda to develop and commercialize NB32 in the United States, Canada and Mexico. We have received $50.0 million from Takeda and we are eligible to receive additional payments of over $1.0 billion upon achieving certain milestones, including $100.0 million that can be achieved between the approval and the first commercial sale of NB32 in the United States. The collaboration agreement provides that Takeda will be responsible for commercialization costs and activities.
We are considering potential partnership opportunities for Empatic as well as NB32 outside of the United States, Canada and Mexico.
For more information about Takeda, visit: www.takeda.com